Benefical Effects of Sigma-1 Agonist Fluvoxamine for Tardive Dyskinesia and Tardive Akathisia in Patients with Schizophrenia: Report of Three Cases

Fluvoxamine is a selective serotonin reuptake inhibitor that is approved for psychiatric disorders such as major depressive episodes and obsessive-compulsive disorder. Beside inhibition of serotonin reuptake, fluvoxamine is also a potent agonist of endoplasmic reticulum (ER) protein sigma-1 receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Albayrak, Yakup, Hashimoto, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Neuropsychiatric Association 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902161/
https://www.ncbi.nlm.nih.gov/pubmed/24474992
http://dx.doi.org/10.4306/pi.2013.10.4.417

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902161/
https://www.ncbi.nlm.nih.gov/pubmed/24474992
http://dx.doi.org/10.4306/pi.2013.10.4.417

Ejemplares similares